High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2 Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis

Background: The pangenotypic direct-acting antivirals (DAAs) glecaprevir and pibrentasvir, comprise the interteron (IFN)- and ribavirin (RBV)-free regimen G/P. In seven phase 2/3 clinical lrials, G/P achieved SVR12 rates of 92-100% across all six major HCV genotypes (GTs). Here we present an integrated analysis from these studies on lhe efficacy of 8 and 12 weeks of G/P treatment in noncirrholic patienls with GT1-6 infection. Methods: Data were pooled from the phase 2 SURVEYOR-I and -11, and phase 3 EXPEDITION-4 and ENDURANCE 1 ,2,3 and 4 sludies. Patients with chronic HCV GT t,2,3,4,5 or 6 infection without cirrhosis received G/P without RBV for either 8 or 12 weeks. Patients were either treatment-naive or treatmenl-experienced with IFN-based or sofosbuvir (SOF)-based regimens. Patients experienced wilh a DAA other than SOF were excluded. Efficacy was evaluated as the rate of sustained virologic response (HCV RNA